 |
Celgene Corporation and its subsidiaries (collectively “we” or “our”) is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID®, THALOMID® and VIDAZA® . REVLIMID® is an oral immunomodulatory drug marketed in the U.S. and Europe for patients with multiple myeloma who have receiv... More >> |
| Date | Title | | | 01/28/10 | Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income|
Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals
REVLIMID(R) Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q
VIDAZA(R) Fourth Quarter Global Net Product Sales Increased 68% Y/Y and 13% Q/Q
Full Year Non-GAAP Diluted Earnings Per Share Increased 33% Y/Y
SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG):
2009 Fourth Quarter Financial Results Year-Over-Y... |
|  | | 01/19/10 | Celgene Corporation to Announce Fourth Quarter and Full-Year 2009
Results on January 28, 2010| SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, January 28, 2010 at
9 a.m. ET to discuss the company's fourth quarter and full-year 2009
financial and operational results. The webcast will be available in the
investor relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 01/15/10 | Celgene Completes Acquisition of Gloucester Pharmaceuticals| Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 millionCommercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its
acquisition of Gloucester Pharmaceuticals following the early
termination of the applicable waiting period u... |
| | | 01/12/10 | Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005
02) Evaluating Treatment with Continuous REVLIMID(R)
in Patients with Multiple Myeloma Following Autologous Stem Cell
Transplant Meets Primary Endpoint| BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that
the Intergroupe Francophone du Myelome and University Hospital of
Toulouse, the sponsor of the study, reported that the independent Data
and Safety Monitoring Committee, of the international Phase III,
randomized, double-blind, multi-center clinical study (IFM 2005 02)
evaluating REVLIMID(R) (lenalidomide) compared to placebo in
multi... |
| |
|
Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever Celgene Corp. posts new information to the site. Just enter your e-mail address and click Submit. |
| |
|
